Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL6582797 | 0.92 | NPC1 (0.56) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| 4-Aminophenol SCHEMBL7014541 | 0.90 | CA9 (0.57) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL28979239 | 0.89 | MAPT (0.53) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29946465 | 0.89 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL6405990 | 0.89 | MAPT (0.58) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL8751 | 0.85 | CA9 (0.62) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL29438605 | 0.85 | CA9 (0.62) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL19391 | 0.82 | AHR (0.67) | DRD2DRD4MAOAMAOBPDE3B | |
| SCHEMBL29533407 | 0.82 | CYP11B1 (0.62) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| Methane SCHEMBL9732811 | 0.81 | AHR (0.65) | MAOAMAOBPDE3BPDE3ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 439 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789596-B | 2,6,10, 14-Tetramethyl pentadecane derivative compound and preparation method and application thereof | Sida Times Pharmaceutical (Suzhou) Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-119841715-A | Method for directly preparing aromatic ether compound from aromatic aldehyde, ketone and phenol | 湖南第一师范学院 | 2025-04-18 | — | — | CN | claimed |
| CN-115784983-B | 6-Amine alkoxy-3, 4-dihydro-quinolinone derivative and preparation method and application thereof | 井冈山大学 | 2024-09-27 | — | — | CN | claimed |
| CN-111285803-B | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2024-04-09 | — | — | CN | claimed |
| CN-116789596-A | 2,6,10, 14-tetramethyl pentadecane derivative compound and preparation method and application thereof | 南京师范大学 | 2023-09-22 | — | — | CN | claimed |
| CN-115784983-A | 6-amine alkoxy-3,4-dihydroquinolinone derivative, preparation method and application thereof | 井冈山大学 | 2023-03-14 | — | — | CN | claimed |
| CN-114984055-A | Periplaneta americana intestinal bacteria metabolite extract, pharmaceutical composition and application of pharmaceutical composition in preparation of drugs for treating cardiovascular and cerebrovascular diseases | 天津中医药大学 | 2022-09-02 | — | — | CN | claimed |
| CN-111208230-B | Method for detecting American cockroach intestinal flora metabolite | 天津中医药大学 | 2022-02-25 | — | — | CN | claimed |
| CN-108383781-B | Synthesis method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolinone | 南京远淑医药科技有限公司 | 2021-07-27 | — | — | CN | claimed |
| CN-111285803-A | Preparation method of 6-hydroxy-3, 4-dihydro-2 (1H) -quinolone | 湖南复瑞生物医药技术有限责任公司 | 2020-06-16 | — | — | CN | claimed |
| EP-1311485-A1 | PROCESSES FOR PREPARING CILOSTAZOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-05-21 | — | — | EP | claimed |
| US-6541487-B1 | Administering 5-bromoquinoline, 5-nitroisoquinoline, 8-nitroisoquinoline, 3,4-dihydro-6-hydroxy-2(1H)-quinolone or 1-methylisoquinoline to relax corpus cavernosa smooth-muscle tissue in males or females | R.T. ALAMO VENTURES I, LLC | 2003-04-01 | — | — | US | claimed |
| US-6525201-B2 | Amidation of p-anisidine with 3-chloropropionyl chloride; cyclization and demtylation of n-(4-methoxyphenyl)-3-chloropropionamide; optimal base/solvent combinations | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-02-25 | — | — | US | claimed |
| US-6515128-B2 | Dissolving 6-hydroxy-3,4-dihydroquinolinone and a base in water; dissolving a 1-cyclohexyl-5- (4-halobutyl)-tetrazole in water-immiscible solvent, mixing aqueous phase and organic phase in presence of phase transfer catalyst; recovering | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-02-04 | — | — | US | claimed |
| US-20020137936-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)3-chloropropionamide | MENDELOVICI MARIOARA (IL) | 2002-09-26 | — | — | US | claimed |
| US-20020099213-A1 | Processes for preparing cilostazol | TEVA PHARMACEUTICALS USA, INC. | 2002-07-25 | — | — | US | claimed |
| WO-2002019997-A1 | PDE III INHIBITORS FOR TREATING SEXUAL DYSFUNCTION | CUTLER NEAL R (US) | 2002-03-14 | — | — | WO | claimed |
| US-20020032333-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | TEVA PHARMACEUTICAL USA, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002014283-A1 | PROCESSES FOR PREPARING CILOSTAZOL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-02-21 | — | — | WO | claimed |
| WO-2001070697-A1 | PROCESSES FOR PREPARING 6-HYDROXY-3,4-DIHYDROQUINOLINONE, CILOSTAZOL AND N-(4-METHOXYPHENYL)-3-CHLOROPROPIONAMIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2001-09-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099213-A1 | Processes for preparing cilostazol | PDE3A, PDE12, PDE5A | NPC1 1826/4885MAPK13 2369/4885MAPK12 2724/4885 |
| US-20020137936-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)3-chloropropionamide | HRH2, HRH3, PDE8B | NPC1 3398/4885MAPK13 2951/4885MAPK12 3038/4885 |
| US-20020032333-A1 | Processes for preparing 6-hydroxy-3,4-dihydroquinolinone, cilostazol and N-(4-methoxyphenyl)-3-chloropropionamide | HRH2, HRH3, HRH4 | NPC1 3583/4885MAPK13 3257/4885MAPK12 3554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.